Impatto del COVID-19 dopo l’inizio della vaccinazione in gruppi di popolazione a rischio, tra cui gli immunocompromessi. Italia 2021-2023
IRIS Research product catalog (Sapienza University of Rome) · 01.01.2024
DOI: 10.53225/ben_073 ↗Kurz gefasst
Fachartikel in der Zeitschrift IRIS Research product catalog (Sapienza University of Rome), erschienen am 01.01.2024. Verfasst von Alberto Mateo Urdiales und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction \nIn Italy, the evidence on the impact of COVID-19 on at-risk population groups is limited. This work details the risks of hospitalization and death from COVID-19 among various at-risk categories after the start of vaccination, including the immunocompromised population, in Italy from 2021 to 2023. \n \n \n \nMaterials and methods \nThis study utilized data from the Integrated COVID-19 Surveillance to obtain the number of hospitalizations and deaths, and data from the National Registry of COVID-19 Vaccinations to identify at-risk population categories. A record linkage was performed between the two data sources using the tax code as a unique identifier. The following health conditions were considered at risk: immunocompromised, hemodialysis, renal failure, nursing home residents, solid tumors, multiple pathologies, and an "other" at-risk category. The risk of hospitalization and death after vaccination was calculated for each category using a Poisson regression model adjusted for age group, gender, geographic area, and with the number of vaccinated individuals as an offset variable. \n \n \n \nResults \nThe highest risk of hospitalization post-vaccination was observed in hemodialysis patients (Incidence Risk Ratio, IRR = 7.1), followed by those with renal failure (IRR = 3.51) and the immunocompromised (IRR=3.23). Similarly, the risk of death among the vaccinated was higher for hemodialysis patients (IRR=8.24), followed by the immunocompromised (IRR=3.93) and those with renal failure (IRR = 3.26). \n \n \n \nDiscussion and conclusions \nAmong the at-risk categories analyzed, the results show that the greatest risk of hospitalization and death from COVID-19 is among those on hemodialysis, those with renal failure, and the immunocompromised. All subjects presenting a risk category, except those in the "other" category, had a higher risk of hospitalization and death from COVID-19 compared to those with no reported risk category. This study represents an initial national-level analysis describing the impact of COVID-19 in terms of risk of hospitalization and death among at-risk population groups
Schlagwörter
Zitieren
APA
Urdiales, A. M., Petrone, D., Manso, M. D., Sacco, C., Fabiani, M., Cannone, A., Angelis, L. D., Fotakis, E. A., Riccardo, F., Pezzotti, P., & Bella, A. (2024). Impatto del COVID-19 dopo l’inizio della vaccinazione in gruppi di popolazione a rischio, tra cui gli immunocompromessi. Italia 2021-2023. IRIS Research product catalog (Sapienza University of Rome). https://doi.org/10.53225/ben_073
Vancouver
Urdiales AM, Petrone D, Manso MD, Sacco C, Fabiani M, Cannone A, et al. Impatto del COVID-19 dopo l’inizio della vaccinazione in gruppi di popolazione a rischio, tra cui gli immunocompromessi. Italia 2021-2023. IRIS Research product catalog (Sapienza University of Rome). 2024. doi:10.53225/ben_073
BibTeX
@article{Urdiales2024,
author = {Urdiales, Alberto Mateo and Petrone, Daniele and Manso, Martina Del and Sacco, Chiara and Fabiani, Massimo and Cannone, Andrea and Angelis, Luigi De and Fotakis, Emmanouil Alexandros and Riccardo, Flavia and Pezzotti, Patrizio and Bella, Antonino},
title = {Impatto del COVID-19 dopo l’inizio della vaccinazione in gruppi di popolazione a rischio, tra cui gli immunocompromessi. Italia 2021-2023},
journal = {IRIS Research product catalog (Sapienza University of Rome)},
year = {2024},
doi = {10.53225/ben_073}
}
EUVIMED